AACR: Antibody-Drug Conjugate Shows Promise in Platinum-Resistant Ovarian Cancer

A novel therapy has shown activity in the treatment of difficult-to-treat, advanced, platinum-resistant ovarian cancer. The drug, DMUC5754A, is part of a new class of drugs called antibody-drug conjugates.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news